Second Genome Clinical Site 408 — Fayetteville, North Carolina

Second Genome Clinical Site 408 is a clinical research site located in Fayetteville, North Carolina, United States 28304.

Crixeo Health Trust Score: 41/100 (POOR). This profile has not yet been claimed by the site owner.

Second Genome Clinical Site 408 has participated in 1 clinical trials.

Therapeutic areas: Nonalcoholic Steatohepatitis.

Sponsors: Second Genome.

Sponsor Feasibility Report

Trust Score: 41/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Second Genome Clinical Site 408?

Second Genome Clinical Site 408 has a Crixeo Trust Score of 41/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Second Genome Clinical Site 408 conducted?

Second Genome Clinical Site 408 has 1 clinical trials on record. Their work covers Nonalcoholic Steatohepatitis.

Is Second Genome Clinical Site 408 accredited by Crixeo Health?

Second Genome Clinical Site 408 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Second Genome Clinical Site 408?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.